Results from an open label clinical study, evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.  The new data is from a phase 2 study reported on Monday, June 2, 2014 at the meeting in Chicago of the American Society of Clinical Oncology (ASCO).

READ FULL ARTICLE Curated publisher From